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Objectives. Oral mucositis is the most severe complication of anticancer therapy. It occurs in 40-85% of patients
during chemotherapy and radiotherapy but also in patients who have undergone hematopoietic stem cell transplanta-
tion. The symptoms for oral mucositis are burning and severe pain oral, spontaneous bleeding, dysphagia, dysarthria
and odynophagia; especially pain and burning sensation on swallowing contribute to decreased quality of life for on-
cologic patients and, in severe cases, may also force the patient to feed parenterally (1). Furthermore, if the mucosi-
tis is severe it can lead to partial or complete interruption of radiotherapy before completion of the treatment protocol
with consequent worsening of the prognosis (2, 3). Dentists must be familiar with the necessary intervents, in order
to help the patient during the course of the treatment and prevent the interruption. Certain measures may help mini-
mize the symptoms associated with oral mucositis; however, further research is required, focusing on lesion preven-
tion prior to treatment initiation. To this end, it has been investigated the salivary proteome of cancer patients who
developed oral mucositis, post chemotherapy and/or radiotherapy. In addition, we compared the salivary proteome of
the same subjects before developing oral mucositis and immediately after the treatment for the mucositis. The analy-
sis was made with SELDI technology. 
Methods. In the current study, 55 saliva samples of patients suffering from different types of cancer were analyzed.
The saliva was collected in three times: before the development of mucositis, when it was diagnosed and after the
resolution of this pathology. All samples were analyzed by SELDI-TOF/MS analysis. It was possible to create cluster
peaks in spectra obtained using BIORAD DataManagerTM software (Ver 3.5).
Results. From this analysis we identified a list of differently expressed mass peaks (clusters). We have selected
some significant peaks in a range of values between 3000 m/z 15000 m/z. In particular, five were found to be differ-
entially expressed: 3343, 3486, 3732, 4132 and 4786 m/z. The analysis of the cluster, we evaluated different pat-
terns of peaks in the three groups; some of these were up regulated, as the peak 3732 m/z in samples pre mucositis,
and down regulated, such as the 7101 m/z in the samples pre mucositis. 
It is noted, moreover, an important increase of the peak 4132 m/z in samples of mucositis.
Conclusions. Oral mucositis is one of the most frequent complications of cancer therapies. It is, therefore, extremely
important that the mucositis is prevented whenever possible, or at least treated to reduce its severity and possible
complications. Knowing the salivary proteome and its variations in a state of pre mucositis, mucositis and post mu-
cositis can be useful in order to intervene with preventive tools and better therapies. The association of the peaks
3343, 3486, 3732, 4132 and 4786 m / z, in particular the increase in expression of the peak 4132 m / z in samples of
mucositis makes us think that it can be used as biomarker of this condition. 
Therefore, if these data will be confirmed on a larger series of patients could identify these proteins and study of tar-
geted therapies. Furthermore, it would be helpful to understand whether these variations are associated with a par-
ticular chemotherapy and evaluate longer available cancer therapies replacement.
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